Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Dec 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called thermal ablation for patients with liver cancer. Thermal ablation uses heat to destroy cancer cells in the liver. The goal of the study is to use advanced technology, like artificial intelligence, to improve how doctors select patients for this treatment, plan the procedure, evaluate its success, and predict outcomes. Researchers hope that by collecting detailed information over the next four years, they can make thermal ablation the preferred treatment for many people with liver tumors.

To be eligible for this study, participants need to be at least 18 years old and have been discussed in a team of doctors as a good candidate for this type of treatment. They also need to be able to provide informed consent, meaning they understand the study and agree to participate. If someone joins the study, they can expect to provide information about their health and undergo imaging tests before, during, and after the procedure to help the researchers gather important data.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or above
• • Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT)
• • Informed consent
• Exclusion Criteria:
• • Patients lacking capacity to give informed consent.